

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

**歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

### **VOLUNTARY ANNOUNCEMENT COLLABORATION AGREEMENT WITH SKY ROAD**

This announcement is made by the board (the “**Board**”) of directors (the “**Director(s)**”) of Zylox-Tonbridge Medical Technology Co., Ltd (the “**Company**” or “**Zylox-Tonbridge**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The Board is pleased to announce that on November 14, 2021, the Company entered into a collaboration agreement (the “**Collaboration Agreement**”) with Hangzhou Sky Road Medical Instrument Co., Ltd\* (杭州天路醫療器械有限公司) (“**Sky Road**”), a China based medical device company and an independent third party of the Company, pursuant to which Sky Road has granted to the Company an exclusive license regarding certain proprietary technology for developing Intravascular Lithotripsy (IVL) system for the treatment of peripheral vascular disease. Pursuant to the Collaboration Agreement, the Company is entitled to, among other things, develop, manufacture, and commercialize the IVL system worldwide, and Sky Road is in return entitled to receive certain economic interests such as upfront, milestone payments and sales royalty.

The technology developed by Sky Road with pending global patent protections will allow Zylox-Tonbridge to develop IVL system for the treatment of medium and heavy calcified arteries, and the data and performance based on the demo system have demonstrated its safety and efficacy. The system includes IVL generator, IVL connector cable, IVL PTA balloon catheter and IVL enhanced drug-eluting balloon catheter, which are the latest additions to our total solution management for lower limb artery diseases. The Company will continue to develop more products and enhance Zylox-Tonbridge's leadership position as a total solution provider to physicians for bringing effective treatments and improving quality of life of patients.

\* *For identification purpose only*

By order of the Board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, November 15, 2021

*As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.*